The international nonprofit organization Population Services International (PSI) and the biopharmaceutical company Pfizer Inc. (NYSE:PFE) today announced Healthy Communities, a US $1 million collaboration to expand access to life-saving hypertension medicines and treatment services in Myanmar and Vietnam.
Approximately one-quarter of all adults in Myanmar and Vietnam have hypertension (1, 2), which can lead to stroke – a leading cause of mortality in both countries. The Healthy Communities program, designed to reduce the barriers that limit hypertension detection, screening, and treatment adherence, aims to incubate sustainable and scalable treatment models and understand how best to support patients and providers.
By Evan Lee, MD, Vice President, Global Health, Eli Lilly and Company
Working in global development, it’s impossible to avoid seeing the heavy personal and societal tolls being wrought by cancer, chronic respiratory disease, diabetes, heart disease, and mental health. These noncommunicable diseases (NCDs) account for three out of every five deaths across the world. The impact is even greater in developing countries, where limited resources and structural barriers hamper access to care.
There is, however, reason to be hopeful. Public health campaigns, supported by commitments through the U.N. Sustainable Developments Goals, are mounting a global response to address these diseases. And much has already been learned about how to tackle the multi-faceted barriers to health care access through collective and coordinated action. As we look to make widespread impact against NCDs, three lessons emerge that should guide our work.
Developing countries are facing a new challenge from an increase in non- communicable diseases (NCDs) such as cardiovascular disease, cancer, mental illness, diabetes and chronic respiratory disorders. At the same time, while substantial gains have been made in the battle against infectious diseases and child and maternal mortality, these remain a major concern, resulting in a double burden of disease.
Produced by The Economist Intelligence Unit, this report is based on extensive data analysis and desk research, complemented by five in-depth interviews with experts on NCDs.
Download the full report.
Visit the Access Accelerated hub on economist.com